The University of Hong Kong Clinical Trials Centre (HKU-CTC) is an academic clinical research organization established under The University of Hong Kong (HKU) in 1998 and has been authorized as the central platform for management and coordination of clinical studies under HKU and its affiliated teaching hospital – Queen Mary Hospital (QMH). HKU-CTC is devoted to partnering with clinical investigators, research organizations and the healthcare industry in advancing human healthcare by promoting, attracting and facilitating clinical studies of various natures. Over the years, HKU-CTC has developed into a leading, full-service professional organization offering one-stop clinical research solutions.
Contact
Address 8/F, Clinical Pathology Building, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong
Tel +852 2255 4664
Website: http://www.hkuctc.com/
Email: ctcentre@hku.hk
Henry Yau, MD and Honorary Assistant Professor at the University of Hong Kong Clinical Trials Centre (HKU-CTC) discusses the center’s development, the diverse range of services it offers, and the…
Hong Kong is repositioning itself within the global innovation landscape, moving beyond its total market-driven model to take an industry policy oriented market-driven approach. Through Office for Attracting Strategic Enterprises…
Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all…
Dr Jeremy Teoh of the Chinese University of Hong Kong leads a research programme spanning bladder cancer biology, surgical innovation, and translational science. From building what is believed to be…
When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed.…
After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the…
It is not unreasonable, at first glance, to ask why so many pharma multinationals have chosen to establish standalone affiliates in Hong Kong. After all, only 7.5 million people call…
Hong Kong – already Asia’s finance hub and an increasingly robust life science R&D destination – is placing huge bets on becoming the region’s prime location for developing, financing, and…
Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were…
In 2026, regulation, policy, institutions, and expertise are aligning to ensure Hong Kong can be a player in an extremely competitive Asian clinical trials landscape. From real-world data studies to…
Amgen’s trajectory in Hong Kong reflects a broader shift underway across the territory’s healthcare landscape, where data-driven care and cross-sector collaboration are converging to accelerate access to innovation. Against the…
Xia JIN, co-founder & CEO of Hong Kong-based immunology biotech Immuno Cure, outlines the progress of its DNA vaccine platform, highlighting strong Phase I results for an HIV therapeutic vaccine…
A biochemistry PhD, Bin Li started out in Merck’s research labs before transitioning to Wall Street, where he was one of the few figures with the scientific, financial, and linguistic…
See our Cookie Privacy Policy Here
